Palvella Therapeutics (PVLA) Free Cash Flow Growth (3y) (2016 - 2026)
Palvella Therapeutics (PVLA) Free Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Palvella Therapeutics | 1.88 Bn | 1.61 Bn | - | 0.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.44% |
| Dec 31, 2025 | 29.40% |
| Sep 30, 2025 | -0.46% |
| Jun 30, 2025 | 30.54% |
| Mar 31, 2025 | 33.52% |
| Dec 31, 2024 | 21.82% |
| Sep 30, 2024 | 43.04% |
| Jun 30, 2024 | -27.12% |
| Mar 31, 2024 | 55.09% |
| Dec 31, 2023 | 51.28% |
| Sep 30, 2023 | -13.31% |
| Jun 30, 2023 | -7.59% |
| Mar 31, 2023 | 13.49% |
| Dec 31, 2022 | 2.73% |
| Sep 30, 2022 | 15.44% |
| Jun 30, 2022 | -11.58% |
| Mar 31, 2022 | -14.79% |
| Dec 31, 2021 | -5.46% |
| Sep 30, 2021 | -0.34% |
| Jun 30, 2021 | 72.84% |